Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
Mark Crowther shared a noteworthy post honoring Dr. Davide Matino, faculty member of McMaster University Department of Medicine, on LinkedIn:
“Incredible breakthroughs are happening right here in Hamilton – and McMaster University is at the heart of it.
A promising new hemophilia treatment – described as “life-transforming”- is being tested on local patients, bringing hope to thousands across Canada.
Leading this cutting-edge clinical trial is Dr. Davide Matino, a faculty member in McMaster University Department of Medicine, which boasts decades of global research excellence in hemostasis and thrombosis.
This isn’t just a milestone in medicine-it’s a powerful reminder of the impact academic research can have when paired with compassion and collaboration.
McMaster’s Faculty of Health Sciences continues to lead the way in advancing care and improving lives, both locally and globally.”
Read more about this exciting development here.
Stay uptaded on hematology world news with Hemostasis Today:
-
Aug 16, 2025, 14:00Iron Deficiency in Polycythemia Vera: William Aird Reveals JAK2-Driven Erythropoiesis as The Key Cause
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 15, 2025, 23:29Cathy Harrison: Launching A Journal Club from EAHAD and WFH
-
Aug 15, 2025, 23:24PERT 2025 Symposium Session XIII: Expert Insights on CTEPH Diagnosis, Surgery and BPA Innovations - Join the Conversation
-
Aug 16, 2025, 16:33RPTH Journal: Dietmar Fries and Colleagues Explore Impact of Long-Distance Trail Running on Blood Markers
-
Aug 16, 2025, 16:15Josepha Clara Sedzro: First Cryo-EM Structure of the Coagulation Initiation Complex
-
Aug 16, 2025, 15:03Abdulla Damluji Highlights ASPREE Trial Update
-
Aug 16, 2025, 14:54Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
-
Aug 16, 2025, 13:42LMWH Use for VTE Prophylaxis in COVID-19 Hospitalized Patients - Multicenter Data from China
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman